<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180909040977N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-01-08</date_registration>
      <primary_sponsor>Gorgan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of leech therapy on carpal tunnel syndrome</public_title>
      <acronym></acronym>
      <scientific_title>A comparison between leech therapy  and medical treatment on clinical symptoms severity as well as nerve and muscle cord changes of patients with carpal tunnel syndrome in moderate grade.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-11-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/33745</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, patients will be allocated to intervention and control groups based on four blocks randomization. The four blocks are entered into the SPSS software, and by mean of the "select random sample" field in SPSS, a one block randomly will be selected, Blinding description: In this study, data analyzer and an assessor who asks questionnaire on the 30th day from patient via telephone are blinded.</study_design>
      <phase>N/A</phase>
      <hc_freetext>The effect of leech therapy on Nerve condition  in carpal tunnel syndrome patients.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group, the patient uses leech therapy in addition to receiving medical treatment (Tablets of Celecoxib 100 mg twice daily, Gabapentin 100 mg twice daily, vitamin B; 300 mg once daily for one month, using short cock-up splint, which should be used at bedtime). Leech therapy will be implemented once, on the first day and in the absence of improvement of pain and clinical symptoms will be used for the second time on the 15th day with the diagnosis of Iranian medicine expert. Four leeches will be placed on the wrist, on anatomical pathway of the medial nerve. Intervention 2: In the control group: the patient was treated purely with medical treatment, including  tablets of Celecoxib 100 mg twice daily, Gabapentin 100 mg twice daily, vitamin B; 300 mg once daily for one month, plus a short cock up splint during sleep will be received.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Decision making in this regard is based on patient information data. By considering the confidentiality of information, decided to publish patient information by the authors will be done at the end of the study. Therefore, a program for the dissemination of information does not exist now</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali akbar Aghaeinejad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Paramedical School, The beginning of the road Shastakla-</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4934174515</zip>
        <telephone>+98 17 3245 1664</telephone>
        <email>dr.aghaeinejad@goums.ac.ir</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Rozbe Shams amiri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>5 Azar Hospital, Azar Avenue,</address>
        <city>Gorgan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4934174515</zip>
        <telephone>+98 17 3222 0561</telephone>
        <email>Rshamsa@gmail.com</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The presence of clinical symptoms and having positive Tinel, Fallen and carpal compersion tests
Having positive paraclinical findings (nerve conduction velocity and electromyography) detected by electrodiagnosis and the grades must be in intermediate level by neurologist and neurologist specialist diagnosis.
Satisfaction should be gained by the use of one of two methods.
Age between 30-60 years</inclusion_criteria>
      <agemin>30 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The presence of rheumatic disease, rheumatoid arthritis and other upper limb disorders, coagulation problems, diabetes, hypothyroidism, gout, lupus erythematosus, acromegaly, chronic kidney failure, and diseases that impede CTS symptoms.
Pregnancy for up to a year and mental retardation and anemia
Frequent fracture or trauma to the wrist and wrist surgery
Injection of intra-articular corticosteroid in the wrists during the past 3 months
Immune system disorders, severe allergic allergy, use of neuropathic drugs, use of non-steroidal anti-inflammatory drugs during the last two weeks
History of stroke syndrome</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G56.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other lesions of median nerve</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group, the patient uses leech therapy in addition to receiving medical treatment (Tablets of Celecoxib 100 mg twice daily, Gabapentin 100 mg twice daily, vitamin B; 300 mg once daily for one month, using short cock-up splint, which should be used at bedtime). Leech therapy will be implemented once, on the first day and in the absence of improvement of pain and clinical symptoms will be used for the second time on the 15th day with the diagnosis of Iranian medicine expert. Four leeches will be placed on the wrist, on anatomical pathway of the medial nerve.</i_keyword>
      <i_keyword>In the control group: the patient was treated purely with medical treatment, including  tablets of Celecoxib 100 mg twice daily, Gabapentin 100 mg twice daily, vitamin B; 300 mg once daily for one month, plus a short cock up splint during sleep will be received.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Abnormalities in electromyography and nerve study. Timepoint: Once on the first day of the study and once on day 60. Method of measurement: Electromyographic machine Nihon kohden model.</prim_outcome>
      <prim_outcome>Pain score on the analog scale visual pain. Timepoint: In 4 steps, at the beginning of the study (before treatment or leech therapy), on day 15, day 30 and day. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Severity of symptoms and functional status. Timepoint: In 4 stages, at the time of entering the study (before treatment or leech therapy), on day 15, day 30 and day 60. Method of measurement: Boston Clinical Symptom Intensity Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Gorgan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-07-29</approval_date>
        <contact_name>Ethics Committee of Golestan University of Medical Sciences</contact_name>
        <contact_address>The beginning of the road is Shastcolaa Gorgan Golestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
